Clinical Trials Logo

Uterine Cervical Neoplasms clinical trials

View clinical trials related to Uterine Cervical Neoplasms.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT05998941 Withdrawn - Cervical Cancer Clinical Trials

A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer

Start date: August 2023
Phase: Phase 2
Study type: Interventional

This study used a single-arm, open phase II multicenter trial design. All eligible subjects received TQB2868 plus platinum-based chemotherapy with or without bevacizumab. A total of 39 subjects will be enrolled.

NCT ID: NCT05614453 Withdrawn - Clinical trials for Metastatic Cervical Cancer

Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy

ITTACC
Start date: June 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn about the effect of the combination treatment of sitravatinib with tislelizumab in patients with Recurrent/Metastatic Cervical Cancer after Platinum-Based Chemotherapy. The main question it aims to answer is the percentage of people in the study who have a partial or complete response to the treatment. Participants will receive treatment under the care of their treating physician and will be reviewed regularly.

NCT ID: NCT05504642 Withdrawn - Clinical trials for Cervical Cancer = FIGO IIB and or Lymph Node Metastases

Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients

CERAD-IMMUNE
Start date: November 1, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to use Chemo-radio-immunotherapy and maintenance therapy with Nivolumab and Ipilimumab in order to achieve improved outcome in patients with locally advanced cervical cancer.

NCT ID: NCT05393635 Withdrawn - Clinical trials for Non-small Cell Lung Cancer

ITIL-168 in Advanced Solid Tumors

DELTA-2
Start date: August 2022
Phase: Phase 1
Study type: Interventional

DELTA-2 is a phase 1 clinical trial to evaluate the safety, feasibility, and preliminary efficacy of ITIL-168 with pembrolizumab in participants with advanced cancer whose disease has progressed after standard therapy. ITIL-168 is a cell therapy derived from a patient's own tumor-infiltrating immune cells (lymphocytes; TILs).

NCT ID: NCT05093712 Withdrawn - Clinical trials for Stage IIA Cervical Cancer FIGO 2018

Patient-Informed Educational Intervention for the Improvement of Cervical Cancer Literacy

Start date: June 28, 2021
Phase:
Study type: Observational

This study investigates the health literacy, cervical cancer knowledge, and radiation knowledge of patients with cervical cancer. The goal of this study is to develop a video that can improve patients 'understanding of cervical cancer and its treatment.

NCT ID: NCT05033132 Withdrawn - Cervical Cancer Clinical Trials

A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer

Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

This is an open-label, multi-center Phase II clinical trial to assess the efficacy, safety, and pharmacokinetics of Balstilimab (Treatment Arm 1 - monotherapy) or in combination with Zalifrelimab (Treatment Arm 2 - combination therapy) for treatment of patients with advanced cervical cancer who relapsed or progressed after receiving first-line platinum-based chemotherapy.

NCT ID: NCT04943627 Withdrawn - Advanced Cancer Clinical Trials

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Start date: August 2, 2021
Phase: Phase 3
Study type: Interventional

This Phase 3 trial is an open-label, randomized study with single-agent Balstilimab (BAL) or Investigator Choice (IC) chemotherapy (single-agent gemcitabine, irinotecan, pemetrexed, vinorelbine, or topotecan) in patients with recurrent, persistent, or metastatic cervical cancer who have progressed after receiving platinum based chemotherapy.

NCT ID: NCT04806945 Withdrawn - Cervical Cancer Clinical Trials

A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer

Start date: September 30, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of HLX10(Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection) plus chemotherapy compared to the efficacy and safety of placebo plus chemotherapy in the treatment of adult women with persistent, recurrent, or metastatic cervical cancer. Chemotherapy regimens include: paclitaxel plus cisplatin and paclitaxel plus carboplatin. The primary study hypotheses are that the combination of HLX10 plus chemotherapy is superior to placebo plus chemotherapy with respect to: 1) Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as assessed by the IRRC or, 2) Overall Survival (OS).

NCT ID: NCT04464967 Withdrawn - Colorectal Cancer Clinical Trials

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Start date: March 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the Phase 1/2a study is to evaluate the safety and tolerability of SNK01 in combination with trastuzumab or cetuximab in order to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the preliminary efficacy for each combination regimen.

NCT ID: NCT04368130 Withdrawn - Ovarian Cancer Clinical Trials

SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care

SIGNAL
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

This research study is testing the use of a smartphone app to identify clinically meaningful changes in the behaviors of patients' with gynecological cancers by using passively collected smartphone data.